• Network Genomic Medicine
  • CIO Cologne Bonn
  • Contact
  • Imprint
  • Privacy Policy
  • English
    • Deutsch
Lung Cancer Group Cologne
  • Who we are
    • Aims
    • Study coordination
    • Team
  • Publications
    • Publications
    • Projects
  • Molecularpathology
    • For patients
    • Molecular Testing
    • Translational Genomics
  • Cologne Conference on Lung Cancer
  • Overview
  • Immunotherapy Trials
Select Page

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

by Sonja Köhler | Apr 22, 2016

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely...

ALK-Diagnostics in NSCLC – Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH)

by Sonja Köhler | Apr 22, 2016

ALK-Diagnostics in NSCLC – Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH) von Laffert M, Schirmacher P, Warth A, Weichert W, Büttner R, Huber RM, Wolf J, Griesinger F, Dietel M, Grohé Ch Journal: Pneumologie Published:  April 1st,...

Clinicopathological characteristics of RET rearranged lung cancer in European patients

by Sonja Köhler | Jan 11, 2016

Clinicopathological characteristics of RET rearranged lung cancer in European patients Sebastian Michels, Andreas Hans Scheel, Matthias Scheffler, Anne Maria Schultheis, Oliver Gautschi, Franziska Aebersold, Joachim Diebold, Georg Pall, Sacha Rothschild, PhD, Lukas...

Find study

  • Genmutation (Marker)

Suche

News-Kategorien

  • Uncategorized (1)

Aktuelle Beiträge

  • SAVE THE DATE: 2nd Cologne Conference on Lung Cancer

The LCGC study center team, led by prof. Juergen Wolf, is located at Dept. I of Internal Medicine in the Center for Integrated Oncology at the University Hospital Cologne. Our goal is to achieve an effective treatment for patients with lung cancer.
For this purpose we are developing our own study reports for treating genetically defined subgroups of lung cancer and to optimize immunotherapy. We do this in close cooperation with the work groups in translational cancer genomics, molecular pathology and molecular imaging.

„NGMCIO Köln BonnUniklinik Köln

Ansprechpartner & Kontaktdaten

Universitätsklinik Köln (AöR)
Klinik I für Innere Medizin

Lung Cancer Group Cologne (LCGC)
am Centrum für Integrierte Onkologie Köln Bonn

Kerpener Str. 62 | 50937 Köln

Tel.: 0221 478 87008

Fax: 0221 478 87010
E-Mail: lungenkrebs@uk-koeln.de

… mehr erfahren Sie hier!

  • © 2015 LungCancerGroupCologne
  • Sitemap
  • Contact
  • Imprint
  • Terms & Conditions
  • Privacy Policy

Designed by Elegant Themes | Powered by WordPress